Physician profile
David Bresticker
NPI 1376582841
$3,087.15
in general payments reported to CMS, 2019-2025
30 companies · $243 in 2025
The $243 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,618 · 2020: $108 · 2022: $304 · 2023: $559 · 2024: $255 · 2025: $243.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,041 · Education: $15.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,041.26 |
| Education | $15.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $492.99 | 2019-2025 | Arexvy, Bexsero, Shingrix |
| Abbvie INC. | $418.24 | 2019-2025 | Ubrelvy, Vraylar, Linzess |
| Pfizer INC. | $246.19 | 2019-2024 | |
| Lilly USA, LLC | $233.61 | 2019-2024 | Mounjaro |
| Amgen INC. | $217.93 | 2019-2025 | Evenity, Prolia |
| Astellas Pharma US INC | $212.93 | 2019-2024 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $191.49 | 2019-2023 | Jardiance, Synjardy, Tradjenta |
| Astrazeneca Pharmaceuticals Lp | $188.82 | 2019-2025 | Breztri |
| Novo Nordisk INC | $150.43 | 2019-2023 | Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $148.26 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $90.49 | 2019-2023 | Eliquis |
| Novartis Pharmaceuticals Corporation | $86.21 | 2019-2022 | |
| Genentech USA, INC. | $38.25 | 2019 | |
| Sanofi-Aventis U.S. LLC | $34.13 | 2019 | |
| Daiichi Sankyo INC. | $32.82 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $31.70 | 2019 | |
| Sanofi Pasteur INC. | $28.51 | 2019 | |
| Amarin Pharma, INC. | $25.42 | 2019 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $24.30 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $23.55 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.68 | 2019 | |
| Phathom Pharmaceuticals, INC. | $19.36 | 2024 | Voquezna |
| Sumitomo Pharma America, INC. | $19.05 | 2025 | Gemtesa |
| Abbott Laboratories | $18.86 | 2019 | |
| Biogen, INC. | $17.93 | 2024 | Plegridy, Avonex, Vumerity |
| Allergan, INC. | $17.06 | 2019 | |
| Mylan Specialty L.P. | $14.62 | 2019 | |
| Hologic Sales and Service, LLC | $13.96 | 2022 | |
| Medtronic, INC. | $13.80 | 2023 | Minimed 780g |
| Braeburn INC. | $13.56 | 2025 | Brixadi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Bresticker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.